Opioids and Animals
FDA published a resource guide to promote responsible opioid prescribing in the treatment of animals.
On August 15, 2018, FDA Commissioner Scott Gottlieb, MD, released a statement expressing the importance of including pain management in animals in the conversation about opioid abuse. Because of a lack of opioids approved by FDA for use in animals, some veterinarians are prescribing opioids to animals that are approved for human use, according to Gottlieb. As part of the agency’s battle against the opioid epidemic, FDA has published a resource for veterinarians to inform them of the potential for humans to misuse products prescribed for animal patients.
The new resource provides information on how to properly safeguard and store these pain medications and how to educate pet parents about the safe storage and disposal of opioids. To combat potential abuse, FDA is “advising veterinarians to develop a safety plan in the event they encounter a situation involving opioid diversion or clients seeking opioids under the guise of treating their pets; and taking steps to help veterinarians spot the signs of opioid abuse.”
“We recognize that opioids and other pain medications have a legitimate and important role in treating pain in animals-just as they do for people. But just like the opioid medications used in humans, these drugs have potentially serious risks, not just for the animal patients, but also because of their potential to lead to addiction, abuse, and overdose in humans who may divert them for their own use,” Gottlieb stated.
FDA is recommending veterinarians use alternatives to opioids, if possible. If veterinarians, however, feel the need to prescribe opioids, FDA recommends they follow all state and federal regulations as well as standards set by the American Veterinary Medical Association.
“Working together, I believe that we can make progress in preventing new cases of addiction while ensuring appropriate and rational prescribing of opioids for human and animal patients with medical need,” Gottlieb stated.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
